Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma

SummaryBackgroundThe peroxisome proliferator-activated receptors (PPAR) are the nuclear hormone receptor superfamily of ligand-activated transcriptional factors. PPAR-gamma (PPARG) activation downregulates production of Th2 type cytokines and eosinophil function. Additionally, treatment with a synthetic PPARG ligand can reduce lung inflammation and IFN-gamma, IL-4, and IL-2 production in experimental allergic asthma. In patients with asthma, PPARG gene expression is known to be associated with the airway inflammatory and remodeling responses. Thus, genetic variants of PPARG may be associated with the development of asthma.MethodsWe genotyped two single nucleotide polymorphisms on the PPARG gene, +34C > G (Pro12Ala) and +82466C > T (His449His), in Korean subjects (839 subjects with asthma and 449 normal controls).ResultsAssociation analysis using logistic regression analysis showed that +82466C > T and haplotypes 1(CC) and 2(CT) were associated with the development of asthma (p = 0.01–0.04). The frequency of PPARG-ht2 was significantly lower in the patients with asthma compared to the normal controls in codominant and dominant models (p = 0.01, pcorr = 0.03 and p = 0.02, pcorr = 0.03, respectively). Conversely, the frequency of PPARG-ht1 was significantly higher in the patients with asthma compared to the normal controls in the codominant model [p = 0.04, OR: 1.27 (1.01–1.6)]. In addition, the rare allele frequency of +82466C > T was significantly lower in patients with asthma in comparison to normal controls in the codominant model (OR: 0.78, p = 0.04). Thus, polymorphism of the PPARG gene may be linked to an increased risk of asthma development.